{
  "protocolSection": {
    "identificationModule": null,
    "descriptionModule": null,
    "conditionsModule": null,
    "designModule": null,
    "armsInterventionsModule": null,
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Safety and tolerability of M5717 in the single ascending dose study",
          "description": "Assessed by frequency and severity of adverse events, and incidence of clinically significant changes and abnormalities in safety laboratory parameters (haematology, coagulation, biochemistry, and urinalysis), vital signs (body temperature, blood pressure, heart rate, and respiratory rate), and 12-lead ECGs",
          "timeFrame": "Up to day 44 (or day 55 for first three cohorts)"
        },
        {
          "measure": "Pharmacokinetic profile of M5717 in the volunteer infection study",
          "description": "Characterized by parameters including maximum observed concentration (Cmax), time to reach Cmax (tmax), area under the concentration-time curve (AUC0-t, AUC0-∞, AUC0-144h), apparent terminal half-life (t1/2), apparent total clearance (CL/F), apparent volume of distribution (Vz/F), time at or above MIC (t≥3 ng/mL), and time at or above minimum parasiticidal concentration (t≥10 ng/mL)",
          "timeFrame": "From dosing (day 1) up to day 44"
        },
        {
          "measure": "Parasite clearance kinetics in the volunteer infection study",
          "description": "Assessed by the parasite reduction ratio (PRR48) and the corresponding parasite clearance half-life",
          "timeFrame": "From dosing (day 1) up to day 21"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pharmacokinetic profile of M5717 in the single ascending dose study",
          "description": "Characterized by parameters including maximum observed concentration (Cmax), time to reach Cmax (tmax), area under the concentration-time curve (AUC0-t, AUC0-∞, AUC0-144h), apparent terminal half-life (t1/2), apparent total clearance (CL/F), apparent volume of distribution (Vz/F), time at or above MIC (t≥3 ng/mL), and time at or above minimum parasiticidal concentration (t≥10 ng/mL)",
          "timeFrame": "From dosing (day 1) up to day 44 (or day 55 for first three cohorts)"
        },
        {
          "measure": "Safety and tolerability of M5717 in the volunteer infection study",
          "description": "Assessed by frequency and severity of adverse events, and incidence of clinically significant changes and abnormalities in safety laboratory parameters (haematology, coagulation, biochemistry, and urinalysis), vital signs (body temperature, blood pressure, heart rate, and respiratory rate), and 12-lead ECGs",
          "timeFrame": "Up to day 44"
        },
        {
          "measure": "Incidence of recrudescence in the volunteer infection study",
          "description": "Incidence of recrudescence of parasitaemia following M5717 dosing",
          "timeFrame": "Up to day 28 after dosing"
        },
        {
          "measure": "Malaria clinical score in the volunteer infection study",
          "description": "Assessment of malaria-related clinical symptoms",
          "timeFrame": "From inoculation (day -8) up to day 44"
        },
        {
          "measure": "Minimum inhibitory concentration (MIC) and minimum parasiticidal concentration",
          "description": "To be calculated using pharmacokinetic-pharmacodynamic modelling",
          "timeFrame": "From dosing (day 1) up to day 44"
        },
        {
          "measure": "Parasite clearance time and lag phase",
          "description": "To be calculated using pharmacokinetic-pharmacodynamic modelling",
          "timeFrame": "From dosing (day 1) up to day 21"
        }
      ],
      "otherOutcomes": [
        {
          "measure": "Genetic mutations in recrudescent Plasmodium falciparum populations",
          "description": "DNA sequence analysis of the P. falciparum eEF2 gene in recrudescent parasites to investigate potential mutations conferring resistance to M5717",
          "timeFrame": "At time of recrudescence (up to day 28 after dosing)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n- Healthy men and women of non-childbearing potential aged 18–55 years\n- For volunteer infection study: participants were required to be malaria naive\n\nExclusion Criteria:\n- For volunteer infection study: individuals who met exclusion criteria associated with previous or concomitant medications and travel to malaria-endemic regions",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "55 Years",
      "stdAges": [
        "ADULT"
      ],
      "studyPopulation": null,
      "samplingMethod": null
    }
  }
}